Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Parallel Study of Comparing WH002 With Paclitaxel Both Sequential of Epirubicin and Cyclophosphamide As Neoadjuvant Treatment of Women With HER2-Negative Breast Cancer

NCT06513364 is registered in ClinicalTrials.gov with Beijing Wehand-Bio Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT06513364
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06513364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Parallel Study of Comparing WH002 With Paclitaxel Both Sequential of Epirubicin and Cyclophosphamide As Neoadjuvant Treatment of Women With HER2-Negative Breast Cancer
Lead sponsor
Beijing Wehand-Bio Pharmaceutical Co., Ltd
Phase
Phase 2
Overall status
Completed
Start date
September 10, 2024
Completion date
November 17, 2025
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer